Tianshu Pharmaceutical, Subsidiary of Nanjing Vcare, Designated as "2025 Hubei SME Technology Center"

2025-07-07

　　Recently, the Hubei Provincial Department of Economy and Information Technology announced the list of enterprises designated as "2025 Hubei SME Technology Centers." Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical), the production base subsidiary of Nanjing Vcare Pharmatech Co., Ltd. (Nanjing Vcare), successfully made the list by leveraging its three major technology platforms: chiral drug synthesis and analysis technology, bio-enzyme engineering technology, and continuous flow engineering technology.

　　The selection of Hubei SME Technology Centers aims to encourage enterprises to strengthen technological innovation, enhance core competitiveness, and promote high-quality industrial development. Guided by its corporate vision of "becoming a globally leading supplier of APIs and advanced intermediates, as well as a comprehensive solution provider," Tianshu Pharmaceutical remains committed to innovation leadership. Centered on differentiated technologies, the company actively explores greener, safer, and smarter advanced engineering technologies in the biopharmaceutical field—such as continuous flow, micro-packed beds, metal catalysis, and bio-enzyme catalysis. This enables Tianshu Pharmaceutical to achieve safe, efficient, and eco-friendly drug production processes, consistently providing customers with more efficient, high-quality, and cost-effective products and services.

　　This designation signifies official recognition of Tianshu Pharmaceutical’s technological innovation capabilities and core competitiveness. It will inject new momentum into the pharmaceutical industry development of Xiangyang City and Hubei Province as a whole.

Prev

Nanjing Vcare's Subsidiary Tianshu Pharmaceutical Officially Enters Trial Production Phase for Phase I Technical Upgrade Project

Next

Tianshu Pharmaceutical, Subsidiary of Nanjing Vcare, Selected to Build "Hubei Provincial High-End API and Pharmaceutical Intermediates CDMO R&D and Pilot-Scale Production Platform"